Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-28

Study Completion Date

2023-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

NCT03958071

Idiopathic Pulmonary Fibrosis

COMPLETED

Investigating Idiopathic Pulmonary Fibrosis in Greece

NCT03074149

Idiopathic Pulmonary Fibrosis

COMPLETED

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

NCT03115619

Idiopathic Pulmonary Fibrosis

COMPLETED

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

NCT05022784

Idiopathic Pulmonary Fibrosis

COMPLETED

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

NCT02230982

Idiopathic Pulmonary Fibrosis

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nintedanib for patients with Idiopathic Pulmonary Fibrosis

Nintedanib

Intervention Type DRUG

diagnosed IPF patients initiating treatment with nintedanib

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nintedanib

diagnosed IPF patients initiating treatment with nintedanib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥40 years of age.
* Patients that have signed Informed Consent Form.
* Treatment naive patients with an initial IPF diagnosis no more than 3 months prior to enrolment according to 2011 American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines who are initiating treatment with nintedanib (as monotherapy for IPF) the latest on the enrollement day or have initiated treatment with nintedanib (as monotherapy for IPF) within the past 7 days prior to enrolment.
* Patients for whom the decision to prescribe therapy with nintedanib according to the locally approved product's Summary of Product Characteristics (SmPC) has already been taken prior to their enrolment in the study and is clearly separated from the physician's decision to include the patient in the current study.
* Patients that are able to read, understand and complete the study specific questionnaires.

Exclusion Criteria

* Treatment with nintedanib for more than 7 days prior to study enrolment.
* Patients receiving a combination therapy of nintedanib \& pirfenidone for IPF.
* Patients that meet any of the contraindications to the administration of the study drug nintedanib according to the approved SmPC.
* Prior treatment with pirfenidone or other treatment for IPF.
* Participation in an interventional study.
* Patients currently receive treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the initiation of therapy with nintedanib.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No